InsiderTrades

Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.

Accepted 2024-02-23 00:00:00 ET · period of report 2024-02-22 · accession 0001856414-24-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-23 2024-02-22 RXRX Marriott Tina Pres, COO M - OptEx $1.06 +8,000 648.0K +1% +$8,480
D 2024-02-23 2024-02-22 RXRX Marriott Tina Pres, COO S - Sale+OE $14.90 -8,000 640.0K -1% -$119.2K
D 2024-02-23 2024-02-22 RXRX Marriott Tina Pres, COO M - OptEx $0.00 -8,000 496.0K -2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2024-02-22 M A 8,000 $1.06 647,982 D — —
2 Common Class A Common Stock 2024-02-22 S D 8,000 $14.90 639,982 D — — (F2) This transaction was executed in multiple trades at prices ranging from $14.42 to $15.19. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3 Derivative Stock Option (Right to Buy) 2024-02-22 M D 8,000 $0.00 496,000 D $1.06 · — to 2028-07-22 8,000 Class A Common Stock (F4) Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.